These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38711520)

  • 21. Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination.
    Fisher DG; Coppock GM; López CB
    Vaccine; 2018 Jun; 36(28):4039-4045. PubMed ID: 29861183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
    Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
    Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.
    Cheong Y; Kim M; Ahn J; Oh H; Lim J; Chae W; Yang SW; Kim MS; Yu JE; Byun S; Jang YH; Seong BL
    Front Immunol; 2021; 12():769088. PubMed ID: 34868027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
    Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice.
    Willis E; Pardi N; Parkhouse K; Mui BL; Tam YK; Weissman D; Hensley SE
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
    J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
    Morçӧl T; Hurst BL; Tarbet EB
    Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
    Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
    Front Immunol; 2020; 11():1207. PubMed ID: 32636840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal vaccination with an adjuvanted polyphosphazenes nanoparticle-based vaccine formulation stimulates protective immune responses in mice.
    Schulze K; Ebensen T; Babiuk LA; Gerdts V; Guzman CA
    Nanomedicine; 2017 Oct; 13(7):2169-2178. PubMed ID: 28579436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.
    Hendy DA; Ma Y; Dixon TA; Murphy CT; Pena ES; Carlock MA; Ross TM; Bachelder EM; Ainslie KM; Fenton OS
    J Control Release; 2024 Aug; 372():168-175. PubMed ID: 38844178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
    Bhatnagar N; Kim KH; Subbiah J; Park BR; Ko EJ; Seong BL; Kang SM
    Antiviral Res; 2022 Jan; 197():105229. PubMed ID: 34933043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines.
    Dong C; Zhu W; Wei L; Kim JK; Ma Y; Kang SM; Wang BZ
    Nat Commun; 2024 Jul; 15(1):5800. PubMed ID: 38987276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
    Rashedi N; Taghizadeh M; Mohamadynejad P; Mahdavi M; Jalalirad R
    Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):497-508. PubMed ID: 33463117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
    Bernasconi V; Norling K; Gribonika I; Ong LC; Burazerovic S; Parveen N; Schön K; Stensson A; Bally M; Larson G; Höök F; Lycke N
    Mucosal Immunol; 2021 Mar; 14(2):523-536. PubMed ID: 32807838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.